Imiquimod 3.75% Cream Applied Daily to Treat Anogenital Warts: Combined Results from Women in Two Randomized, Placebo-Controlled Studies

Table 1

Demographic and external anogenital wart characteristics by treatment group, all women.

Women	Placebo	Imiquimod 2.5%	Imiquimod 3.75%	𝑃 value
	106	212	216
Age, years
Mean (standard deviation)	32.9 (12.2)	32.8 (11.6)	34.2 (13.1)	0.462^a
Median (range)	29 (18–75)	30 (17–78)	31 (15–81)
Race, 𝑛 (%)
White	71 (67.0)	132 (62.3)	157 (72.7)	0.107^b
Black/African American	34 (32.1)	74 (34.9)	52 (24.1)
Other	1 (0.9)	6 (2.8)	7 (3.2)
Total wart area, mm^2
Mean (standard deviation)	166.5 (303.0)	161.9 (362.1)^c	170.6 (463.0)	0.975^a
Median (range)	57 (6–1969)^d	55 (10–4000)^c	50 (10–5579)
Wart count, 𝑛
Mean (standard deviation)	8.3 (7.7)	7.9 (6.3)^c	7.8 (6.1)	0.751^a
Median (range)	5 (2–30)	6 (2–30)^c	6 (2–30)
Duration since first EGW diagnosis, years
Mean (standard deviation)	5.5 (8.3)	5.7 (7.8)	5.5 (8.1)	0.967^a
Median (range)	1.4 (0.0–33.7)	2.1 (0.0–31.4)	1.6 (0.0–39.4)
First episode, 𝑛 (%)
Yes	79 (74.5)	151 (71.2)	140 (64.8)	0.152^b
Anatomical locations involved, 𝑛 (%)
1 only	54 (50.9)	93 (43.9)	96 (44.4)	0.451^b
2 or more	52 (49.1)	119 (56.1)	120 (55.6)
Vulvar	63 (59.4)^e	138 (65.1)^e	145 (67.1)^e
Inguinal	10 (9.4)^e	30 (14.2)^e	28 (13.0)^e
Perineal	51 (48.1)^e	96 (45.3)^e	109 (50.5)^e
Perianal	48 (45.3)^e	103 (48.6)^e	97 (44.9)^e
Perineal	51 (48.1)^e	96 (45.3)^e	109 (50.5)^e

^a𝑃 value from an ANOVA 𝐹test.
^b𝑃 value from a Chi-square test.
^cOne woman without wart data at baseline; wart count from screening used with no total area available.
^dOne woman with wart area <10 mm².
^eA woman may have more than one site involved, so total across anatomic sites may exceed 100%.